Patent application number | Description | Published |
20080249083 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes. | 10-09-2008 |
20100009337 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes. | 01-14-2010 |
20100021478 | DIAGNOSTIC ANTIBODY ASSAY - The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 01-28-2010 |
20100028918 | GLUTAMINYL CYCLASE AS A DIAGNOSTIC/PROGNOSTIC INDICATOR FOR NEURODEGENERATIVE DISEASES - A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided. | 02-04-2010 |
20100099721 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Inhibitors of prolyl endopeptidase of formula 1 | 04-22-2010 |
20100119478 | ANTIBODIES DIRECTED AGAINST PYROGLUTAMATE MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1 N1pE) - Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE) are described. | 05-13-2010 |
20100125086 | USE OF ISOQC INHIBITORS - The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinising polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation. | 05-20-2010 |
20120064547 | DIAGNOSTIC ANTIBODY ASSAY - Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 03-15-2012 |
20130302835 | ANTIBODIES DIRECTED AGAINST PYROGLUTAMATE MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1 N1pE) - Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE). | 11-14-2013 |
Patent application number | Description | Published |
20110166035 | NOVEL DIAGNOSTIC METHOD - Provided herein are methods, compositions, and kits related to the detection and diagnosis of a neurodegenerative disorder, such as Alzheimer's disease. Various aspects use the oligomeric state of fragments of amyloid β as a biomarker and further concerns a novel method to determine the oligomeric state of fragments of amyloid β in biological samples. | 07-07-2011 |
20110212853 | NOVEL DIAGNOSTIC METHOD - A method of monitoring treatment of an inflammatory disease or an inflammatory associated disease with the use of the ratio of N-terminal pyroglutamate modified MCP-1 (MCP-1 N1pE):total concentration of MCP-1 within a biological sample as a biomarker, and a method for determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 in biological samples. Also disclosed are a diagnostic kit and a method for screening a glutaminyl cyclase (QC) inhibitor or measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor. | 09-01-2011 |
20120183974 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes. | 07-19-2012 |